EXCLUSIVE: Adial Pharmaceuticals' Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety, Patient Compliance
Portfolio Pulse from Vandana Singh
Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced positive clinical results for AD04, its lead investigational drug for Alcohol Use Disorder (AUD), showing a strong safety profile, high patient compliance, and no significant adverse effects. The study compared AD04's liver safety profile to a placebo in subjects with AUD, revealing no significant changes in liver injury markers. Additionally, ADIL received a U.S. patent in February for AD04 targeting the serotonin transporter gene for opioid use disorder treatment.
April 10, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADIL announced encouraging results for AD04 in treating AUD, highlighting its safety and compliance, alongside receiving a U.S. patent for AD04 in opioid disorder treatment.
The positive clinical results and the new U.S. patent for AD04 position ADIL favorably in the market. The strong safety profile and high compliance of AD04 in treating AUD, combined with the strategic expansion of its application to opioid use disorder, could attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100